free counter
Health And Medical

New method mass-produces antitumor cells to take care of blood diseases and cancer

New patent-pending method mass-produces antitumor cells to treat blood diseases and cancer
Xiaoping Bao, Purdue University assistant professor from the Davidson School of Chemical Engineering. Credit: Xiaoping Bao

A Purdue University chemical engineer has superior traditional solutions to produce off-the-shelf human immune cells that show strong antitumor activity, in accordance with a paper published in the peer-reviewed journal Cell Reports.

Xiaoping Bao, a Purdue University assistant professor from the Davidson School of Chemical Engineering, said CAR-neutrophils, or chimeric antigen receptor neutrophils, and engraftable HSCs, or , work forms of therapies for blood diseases and cancer. Neutrophils will be the most abundant white cell blood type and effectively cross physiological barriers to infiltrate solid tumors. HSCs are specific progenitor that may replenish all blood lineages, including neutrophils, throughout life.

“These cells aren’t designed for broad clinical or research use due to the difficulty to expand ex vivo to an adequate number necessary for infusion after isolation from donors,” Bao said. “Primary neutrophils especially are resistant to genetic modification and also have a brief half-life.”

Bao is rolling out a patent-pending solution to mass-produce CAR-neutrophils from human pluripotent stem cells (hPSCs), that’s, cells that self-renew and so are in a position to become any kind of human cell. The chimeric antigen receptor constructs were engineered expressing at first glance of the hPSCs, that have been directed into functional CAR-neutrophils by way of a novel, chemically defined protocol.

The technique was made in collaboration with Qing Deng at Purdue’s Department of Biological Sciences, Hal E. Broxmeyer, now deceased, at Indiana University School of Medicine, and Xiaojun Lian at the Pennsylvania State University.

“We developed a robust protocol for massive production of de novo neutrophils from ,” Bao said. “These hPSC-derived neutrophils displayed superior and specific antitumor activities against glioblastoma after engineering with chimeric antigen receptors.”

Bao disclosed the innovation to the Purdue Research Foundation Office of Technology Commercialization, which includes applied for a global patent beneath the Patent Cooperation Treaty system of the planet Intellectual Property Organization. The innovation has been optioned to an Indiana-headquartered life sciences company.

“We shall also use Dr. Timothy Bentley, professor of neurology and neurosurgery,and his team at the Purdue College of Veterinary Medicine to perform clinical trials in most dogs with spontaneous glioma,” Bao said.

More info: Yun Chang et al, Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy, Cell Reports (2022). DOI: 10.1016/j.celrep.2022.111128

Citation: New method mass-produces antitumor cells to take care of blood diseases and cancer (2022, August 3) retrieved 3 August 2022 from

This document is at the mercy of copyright. Aside from any fair dealing for the intended purpose of private study or research, no part could be reproduced minus the written permission. This content is provided for information purposes only.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker